Please ensure Javascript is enabled for purposes of website accessibility

3 Great Dividend Stocks You Can Buy for Less Than $50

By Keith Speights - Jun 6, 2021 at 5:52AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A little up-front money can quickly begin making you money with these stocks.

A lot of companies pay you to own their stocks. Most of them hand over money to you every quarter. I'm referring, of course, to dividend stocks.

You might think that these stocks would inherently cost a lot more. Sure, there are plenty of stocks with attractive dividends that have high share prices. There are exceptions, though. Here are three great dividend stocks you can buy for less than $50.

Hand holding $50 bill folded in half

Image source: Getty Images.

Brookfield Renewable

You have a choice with investing in Brookfield Renewable (BEP -1.60%) (BEPC -1.61%). The company's shares are available through its limited partnership (LP), which has the ticker of BEP. It also offers shares of a corporate structure with the ticker BEPC that doesn't have some of the tax headaches associated with LPs. Both stocks reflect the same underlying business. Either of them can currently be bought for around $40 per share.

Brookfield Renewable Partners (the LP) pays a dividend yield of 3%. That's a little higher than the 2.84% yield for Brookfield Renewable Corporation, but only because of the differences in the share prices. The dividend (or distribution) payment is exactly the same with either stock.

As its name indicates, Brookfield Renewable supplies renewable energy. There are several reasons to invest in renewable energy stocks, but probably the best reason (and certainly the top reason for Brookfield Renewable) is the near-certainty of strong future growth.

Brookfield Renewable currently operates hydroelectric, wind, and solar facilities with around 21,000 megawatts of capacity. Its development pipeline, though, more than doubles that amount with 27,000 megawatts of planned capacity. The company projects that it will be able to deliver total returns of between 12% and 15% over the long term. That goal seems attainable. 

Enterprise Products Partners

Enterprise Products Partners (EPD -1.45%) is a different kind of energy stock than Brookfield Renewable. It's one of the top midstream energy companies, operating pipelines, processing, and storage facilities for natural gas, natural gas liquids, crude oil, and petrochemicals.

You can scoop up a couple of shares with $50 at EPD's current price. The stock offers an especially juicy dividend yield of 7.4%. Even better, EPD has increased its dividend for 22 consecutive years. 

But could fossil fuels go the way of the dinosaur? Maybe over time. However, EPD should remain strong as lower-emission natural gas and NGLs, along with lower sulfur crude oil and petrochemicals, continue to enjoy robust demand globally.

The company also sees growth opportunities in environmentally friendly areas such as hydrogen and carbon capture and storage. With its tremendous dividend and growth prospects, EPD just might be able to double your money within the next decade.


One share of Pfizer (PFE 1.12%) will cost you less than $40 right now. For that price, you'll pick up one of the best dividends in the healthcare sector. Pfizer's dividend currently yields north of 4%.

Until recently, it seemed a foregone conclusion that the big drugmaker would reduce its dividend somewhat. Pfizer had stated that would happen when Viatris initiated its dividend program. Viatris was formed in November 2020 by the merger of Pfizer's Upjohn business with Mylan. However, Pfizer's exceptionally strong Q1 results and upbeat guidance allowed it to forego a dividend cut.

The success of the COVID-19 vaccine developed by Pfizer and its partner, BioNTech, has dramatically changed the dynamics for Pfizer. This vaccine is on track to generate sales of at least $26 billion in 2021. Pfizer records the sales but splits profits equally with BioNTech.

What about the future for Pfizer? The company should enjoy strong growth over the next five years, especially if annual COVID-19 vaccines are needed as expected. It faces the losses of basic U.S. patents for several drugs beginning in 2025, though. Still, investors shouldn't have anything to worry about with Pfizer's dividend.

Keith Speights owns shares of Brookfield Renewable Corporation Inc., Brookfield Renewable Partners L.P., Enterprise Products Partners, Pfizer, and Viatris Inc. The Motley Fool recommends Enterprise Products Partners and Viatris Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$49.12 (1.12%) $0.55
Enterprise Products Partners L.P. Stock Quote
Enterprise Products Partners L.P.
$26.91 (-1.45%) $0.40
Brookfield Renewable Partners L.P. Stock Quote
Brookfield Renewable Partners L.P.
$38.74 (-1.60%) $0.63
BioNTech SE Stock Quote
BioNTech SE
$148.22 (0.41%) $0.61
Brookfield Renewable Corporation Inc. Stock Quote
Brookfield Renewable Corporation Inc.
$40.86 (-1.61%) $0.67
Viatris Inc. Stock Quote
Viatris Inc.
$10.56 (-0.24%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.